Late stage pipeline
Focus on innovation and science to unlock mid-term potential
Pipeline updated as of May 2025
| Molecule name | Indication | Phase I | Phase II | Phase III | Registration | Geography |
|---|---|---|---|---|---|---|
| Life-cycle management (label extension) | ||||||
|
Tirbanibulin
|
Actinic keratosis (Large Field)
|
|
|
|||
|
Tildrakizumab
|
Psoriatic arthritis
|
|
|
|||
|
Lebrikizumab
|
Atopic Dermatitis pediatric
|
|
|
|||
| New molecular entities (NMEs) | ||||||
|
Anti-IL-1RAP mAb
|
Hidradenitis suppurativa
|
|
|
|||
|
Anti-IL-1RAP mAb
|
Inflammatory skin disease
|
|
|
|||
|
Anti-IL-21 mAb
|
Hidradenitis suppurativa
|
|
|
|||
|
IL-2muFc
|
Alopecia areata
|
|
*
|
|||
|
IL-2muFc
|
Atopic dermatitis
|
|
**
|
|||
|
IL-2muFc
|
Inflammatory skin disease
|
|
*
|
|||
|
Readthrough inducer
|
Rare dermatology (RDEB/JEB)***
|
|
|
|||
|
Anti-IL-13/OX40L BsAb
|
Atopic dermatitis
|
|
|
|||
|
SMOL oral
|
Th2-driven diseases
|
|
|
|||
|
mRNA/LNP
|
Non-melanoma skin cancer
|
|
|
|||
* Worldwide ex-Greater China
** Atopic dermatitis trial conducted by our partner SIMCERE
*** RDEB / JEB: Recessive Dystrophic / Junctional Epidermolysis BullosaSMOL: Small Molecules, mRNA: Messenger RNA, LNP: Lipid Nanoparticle